Press Releases
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
07/18/17Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 9, 2017 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (888)698-6931 (U.S.) or (805)905-2993 (International) and refer to Conference ID: 5785-1943.  An audio webc... 
Printer Friendly Version
06/08/17Collegium Announces Scientific Presentations at the 2017 International Conference on Opioids
CANTON, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the 2017 International Conference on Opioids taking place in Boston, MA. The following posters will be presented during the poster sessions on Sunday, June 11th and Monday, June 12th. Poster #16 titled, “Assessment of the oral human abuse liability and... 
Printer Friendly Version
06/01/17Collegium Announces Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients
CANTON, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that one of the largest managed care organizations with approximately 8 million Medicare Part D lives has added Xtampza® ER to its Medicare Part D formularies.  Effective June 1, 2017, Xtampza ER is the exclusive oxycodone extended-release product for this organization’s Part D plan designs. “Expanding managed care coverage is a critical component of our strategy.  With this formula... 
Printer Friendly Version
05/30/17Collegium Announces the Appointment of Joseph Ciaffoni as Chief Operating Officer
CANTON, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Joseph Ciaffoni to the newly created position of Executive Vice President and Chief Operating Officer, effective May 31, 2017. “We are excited to have Joe join Collegium in this newly created role,” said Mike Heffernan, Collegium’s CEO. “Joe’s industry experience is extensive and includes building commercial businesses, leading emerging growth and multi-national orga... 
Printer Friendly Version
05/23/17Collegium to Present at Upcoming Investor Conferences
CANTON, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: The Jefferies 2017 Global Healthcare Conference on Tuesday, June 6th at 9:00 a.m. ET in New York City The 37th Annual William Blair Growth Stock Conference on Wednesday, June 14th at 2:40 p.m. CT at The Four Seasons Hotel Chicago About Collegium Pharmaceutical, Inc. Collegium is a specialty ph... 
Printer Friendly Version
05/10/17Collegium Reports First Quarter Financial Results and Provides Corporate Update
Xtampza® ER prescribed by more than 3,000 physicians since commercial launch Xtampza ER Notice of Allowance granted and, once issued, will extend patent protection until 2030 Well capitalized with $129.6 million in cash and cash equivalents Conference call scheduled for today at 4:30 p.m. ET CANTON, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the first quarter of 2017 and provided a corporate update.... 
Printer Friendly Version
05/03/17Collegium to Host Conference Call to Discuss First Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., May 03, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (888)698-6931 (U.S.) or (805)905-2993 (International).  An audio webcast will be accessible from the Investor ... 
Printer Friendly Version
04/20/17Collegium to Present at the 42nd Annual Deutsche Bank Healthcare Conference
CANTON, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 42nd Annual Deutsche Bank Healthcare Conference in Boston. The presentation will take place at 10:40 a.m. ET on Wednesday, May 3, 2017 at the InterContinental Boston Hotel. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technolog... 
Printer Friendly Version
04/04/17Collegium Announces Appointment of Steven Passik, PhD, as Vice President, Scientific Affairs, Education and Policy
CANTON, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced it has appointed Steven Passik, PhD, as Vice President of Scientific Affairs, Education and Policy, effective, April 3, 2017. “We are excited to announce the addition of Steve to the executive team. He will bring a wealth of additional experience in the fields of pain and addiction management to the team at Collegium. We are looking forward to his contributions toward our vision of... 
Printer Friendly Version
04/03/17Collegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D Patients
CANTON, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that a large national managed care organization with more than 3 million Medicare Part D lives has added Xtampza® ER to its Medicare Part D formularies.  Effective April 1, 2017, Xtampza ER is the exclusive branded oxycodone extended-release product for this organization’s Part D plan designs. This plan, along with previous formulary additions, continues to expand Xtampza ER’s total c... 
Printer Friendly Version
03/28/17Collegium to Present at the 16th Annual Needham Healthcare Conference
CANTON, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 16th Annual Needham Healthcare Conference in New York City. The presentation will take place at 10:40 a.m. ET on Wednesday, April 5, 2017 at the Westin New York Grand Central Hotel. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® ... 
Printer Friendly Version
03/16/17Collegium Announces Scientific Presentation at American Academy of Pain Medicine 2017 Meeting
CANTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the 33rd Annual American Academy of Pain Medicine Meeting on March 16th in Orlando. The poster titled, “Converting Subjects with Chronic Pain from Immediate-Release Oxycodone to Xtampza ER, an Extended-Release, Abuse-Deterrent Formulation,” is a post hoc a... 
Printer Friendly Version
03/09/17Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
Xtampza® ER prescribed by more than 2,400 physicians since commercial launch ONSOLIS® patent issued that extends patent protection until 2027 Well capitalized with $153.2 million in cash and cash equivalents CANTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the fourth quarter of 2016 and provided a corporate update.  “We have made significant progress on the commercial launch of Xtampza ER. Through... 
Printer Friendly Version
02/28/17Collegium to Host Conference Call to Discuss 2016 Financial Results and Provide Corporate Update
CANTON, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, March 9, 2017 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (888)698-6931 (U.S.) or (805)905-2993 (International).  An audio webcast will be accessible from the Investor... 
Printer Friendly Version
02/01/17Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER
CANTON, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from an oral human abuse potential clinical trial, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of Xtampza® ER (oxycodone extended-release capsules) compared to chewed Xtampza ER, and crushed immediate-release oxycodone in solution in non-dependent, recreational drug abusers.  The study met its primary and secon... 
Printer Friendly Version